Perrigo Company Gets a Hold Rating from Jefferies

By Ryan Adsit

In a report released yesterday, Steven Desanctis from Jefferies reiterated a Hold rating on Perrigo Company (NYSE: PRGO), with a price target of $71. The company’s shares closed yesterday at $73.07.

According to, Desanctis is a 1-star analyst with an average return of -0.4% and a 50.0% success rate. Desanctis covers the Basic Materials sector, focusing on stocks such as Southwestern Energy, Pioneer Natural, and Albemarle Corp.

Perrigo Company has an analyst consensus of Hold, with a price target consensus of $73.

Based on Perrigo Company’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $1.35 billion and GAAP net loss of $1.26 billion. In comparison, last year the company earned revenue of $1.38 billion and had a GAAP net loss of $335 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences. The CHC segment includes the company’s former segments, which are the Nutritionals and Israel Pharmaceuticals and Diagnostics business. The BCH segment consists of the Omega business. The Prescription Pharmaceuticals includes the Rx Pharmaceuticals business. The Specialty Sciences segment comprises of the assets, which focuses on the treatment of multiple sclerosis. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.